SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) typically lacks target-driven gene alterations and are primarily resistant to cytotoxic drugs. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.